Acute Myeloid Leukemia Panel by FISH
Also known as: FISHAML
Use
Used to identify cytogenetic abnormalities with diagnostic and prognostic significance in suspected or newly diagnosed acute myeloid leukemia (AML). These abnormalities can have implications for patient diagnosis and can help monitor therapeutic response, making it an essential test for managing AML treatment strategies.
Special Instructions
The test automatically includes the PML/RARA probe, which is performed with the panel but reported and charged separately due to its longer turnaround time. Clinical indication or reason for testing, as well as specimen type, must accompany the test order to ensure appropriate processing. However, testing will proceed in the absence of this information, although culturing and reporting may be impacted.
Limitations
The test assesses specific cytogenetic abnormalities; results should be interpreted in conjunction with clinical and other laboratory findings. It does not cover every genetic variant associated with AML, and abnormalities outside the assay's target regions will not be detected. Delayed or compromised culturing and reporting may occur if initial processing information is incomplete or incorrect.
New York Approved
Methodology
Chromosomal / Cytogenetics (FISH)
Biomarkers
Result Turnaround Time
3-9 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
3 mL
Minimum Volume
1 mL
Container
heparinized syringe or green (sodium heparin) tube
Collection Instructions
Collect nondiluted bone marrow aspirate in a heparinized syringe and transfer to a green (sodium heparin) tube.
Storage Instructions
Store and transport at room temperature.
Causes for Rejection
Clotted or paraffin-embedded specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 48 hours |
| Frozen | Unacceptable |